Literature DB >> 11435325

Expression of p15(ink4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors.

L Teofili1, M Martini, A Di Mario, S Rutella, R Urbano, M Luongo, G Leone, L M Larocca.   

Abstract

In myelodysplastic syndrome (MDS), the expression of the cyclin-dependent kinase inhibitor p15(ink4B) (p15) is frequently decreased because of the aberrant methylation of the gene promoter; p15 is normally up-regulated during megakaryocytic differentiation. It was hypothesized that p15 methylation and deregulation of gene expression contribute to defective megakaryocytopoiesis in patients with MDS. Here it is shown that the increasing autocrine production of TGF-beta1 stimulates megakaryocytic differentiation in normal CD34(+) cells and that p15 mediates, at least in part, this effect. This TGF-beta1-dependent pathway is altered in MDS CD34(+) progenitors because of p15 methylation. The demethylating agent 2-deoxyAZAcytidin can restore the normal demethylated state of the p15 gene and increase its expression. Nevertheless, MDS CD34(+) cells only poorly differentiate to the megakaryocytic lineage. These findings suggest that p15 methylation occurs in a neoplastic clone with a profound defect of cell proliferation, survival, and differentiation that cannot be overcome by using a demethylating drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435325     DOI: 10.1182/blood.v98.2.495

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Epigenetic inactivation of tumor suppressor genes in hematologic malignancies.

Authors:  Tomohiro Kinoshita
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

2.  Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.

Authors:  Andrew G Muntean; Liyan Pang; Mortimer Poncz; Steven F Dowdy; Gerd A Blobel; John D Crispino
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

Review 3.  DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.

Authors:  Elizabeth A Griffiths; Steven D Gore
Journal:  Semin Hematol       Date:  2008-01       Impact factor: 3.851

4.  Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes.

Authors:  Kavita Raj; Ghulam J Mufti
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

5.  miR-125b modulates megakaryocyte maturation by targeting the cell-cycle inhibitor p19INK4D.

Authors:  Mingyi Qu; Fang Fang; Xiaojing Zou; Quan Zeng; Zeng Fan; Lin Chen; Wen Yue; Xiaoyan Xie; Xuetao Pei
Journal:  Cell Death Dis       Date:  2016-10-20       Impact factor: 8.469

6.  p15Ink4b Loss of Expression by Promoter Hypermethylation Adds to Leukemogenesis and Confers a Poor Prognosis in Acute Promyelocytic Leukemia Patients.

Authors:  Shahid M Baba; Niyaz A Azad; Zafar A Shah; Arshad A Pandith; Aleem Jan; Sheikh A Aziz
Journal:  Cancer Res Treat       Date:  2016-12-05       Impact factor: 4.679

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.